Literature DB >> 17549751

Including sampling and phenotyping costs into the optimization of two stage designs for genomewide association studies.

Hans-Helge Müller1, Roman Pahl, Helmut Schäfer.   

Abstract

We propose optimized two-stage designs for genome-wide case-control association studies, using a hypothesis testing paradigm. To save genotyping costs, the complete marker set is genotyped in a sub-sample only (stage I). On stage II, the most promising markers are then genotyped in the remaining sub-sample. In recent publications, two-stage designs were proposed which minimize the overall genotyping costs. To achieve full design optimization, we additionally include sampling costs into both the cost function and the design optimization. The resulting optimal designs differ markedly from those optimized for genotyping costs only (partially optimized designs), and achieve considerable further cost reductions. Compared with partially optimized designs, fully optimized two-stage designs have higher first-stage sample proportion. Furthermore, the increment of the sample size over the one-stage design, which is necessary in two-stage designs in order to compensate for the loss of power due to partial genotyping, is less pronounced for fully optimized two-stage designs. In addition, we address the scenario where the investigator is interested to gain as much information as possible, however is restricted in terms of a budget. In that we develop two-stage designs that maximize the power under a certain cost constraint. (c) 2007 Wiley-Liss, Inc.

Mesh:

Year:  2007        PMID: 17549751     DOI: 10.1002/gepi.20245

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  5 in total

1.  Probability that a two-stage genome-wide association study will detect a disease-associated snp and implications for multistage designs.

Authors:  M H Gail; R M Pfeiffer; W Wheeler; D Pee
Journal:  Ann Hum Genet       Date:  2008-07-24       Impact factor: 1.670

2.  Methodological Issues in Multistage Genome-wide Association Studies.

Authors:  Duncan C Thomas; Graham Casey; David V Conti; Robert W Haile; Juan Pablo Lewinger; Daniel O Stram
Journal:  Stat Sci       Date:  2009-11-01       Impact factor: 2.901

3.  Robust joint analysis allowing for model uncertainty in two-stage genetic association studies.

Authors:  Dongdong Pan; Qizhai Li; Ningning Jiang; Aiyi Liu; Kai Yu
Journal:  BMC Bioinformatics       Date:  2011-01-07       Impact factor: 3.169

4.  The cost effectiveness of duplicate genotyping for testing genetic association.

Authors:  Nathan Tintle; Derek Gordon; Dirk Van Bruggen; Stephen Finch
Journal:  Ann Hum Genet       Date:  2009-03-25       Impact factor: 1.670

5.  Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data.

Authors:  Ramachandran S Vasan; Nicole L Glazer; Janine F Felix; Wolfgang Lieb; Philipp S Wild; Stephan B Felix; Norbert Watzinger; Martin G Larson; Nicholas L Smith; Abbas Dehghan; Anika Grosshennig; Arne Schillert; Alexander Teumer; Reinhold Schmidt; Sekar Kathiresan; Thomas Lumley; Yurii S Aulchenko; Inke R König; Tanja Zeller; Georg Homuth; Maksim Struchalin; Jayashri Aragam; Joshua C Bis; Fernando Rivadeneira; Jeanette Erdmann; Renate B Schnabel; Marcus Dörr; Robert Zweiker; Lars Lind; Richard J Rodeheffer; Karin Halina Greiser; Daniel Levy; Talin Haritunians; Jaap W Deckers; Jan Stritzke; Karl J Lackner; Uwe Völker; Erik Ingelsson; Iftikhar Kullo; Johannes Haerting; Christopher J O'Donnell; Susan R Heckbert; Bruno H Stricker; Andreas Ziegler; Thorsten Reffelmann; Margaret M Redfield; Karl Werdan; Gary F Mitchell; Kenneth Rice; Donna K Arnett; Albert Hofman; John S Gottdiener; Andre G Uitterlinden; Thomas Meitinger; Maria Blettner; Nele Friedrich; Thomas J Wang; Bruce M Psaty; Cornelia M van Duijn; H-Erich Wichmann; Thomas F Munzel; Heyo K Kroemer; Emelia J Benjamin; Jerome I Rotter; Jacqueline C Witteman; Heribert Schunkert; Helena Schmidt; Henry Völzke; Stefan Blankenberg
Journal:  JAMA       Date:  2009-07-08       Impact factor: 56.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.